Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Por Sapin, Christophe, Hartry, Ann, Kamat, Siddhesh A., Beillat, Maud, Baker, Ross A., Eramo, Anna
Publicado no Drugs Context (2016)

Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

Por Stephenson Judith J, Kern David M, Agarwal Sonalee S, Zeidman Ruth, Rajagopalan Krithika, Kamat Siddhesh A, Foley John
Publicado em 2012-12-01

Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

Por Stephenson, Judith J, Kern, David M, Agarwal, Sonalee S, Zeidman, Ruth, Rajagopalan, Krithika, Kamat, Siddhesh A, Foley, John
Publicado em 2012

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia

Por Wilson, Michele, Gutierrez, Benjamin, Offord, Steve J., Blanchette, Christopher M., Eramo, Anna, Earnshaw, Stephanie, Kamat, Siddhesh A.
Publicado no Drugs Context (2016)

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients

Por Kamat, Siddhesh A, Offord, Steve, Docherty, John, Lin, Jay, Eramo, Anna, Baker, Ross A, Gutierrez, Benjamin, Karson, Craig
Publicado no Drugs Context (2015)

Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications

Por Llorca, Pierre-Michel, Lançon, Christophe, Hartry, Ann, Brown, T. Michelle, DiBenedetti, Dana B., Kamat, Siddhesh A., François, Clément
Publicado no BMC Psychiatry (2017)

Lack of tolerable treatment options for patients with schizophrenia

Por Citrome, Leslie, Eramo, Anna, Francois, Clement, Duffy, Ruth, Legacy, Susan N, Offord, Steve J, Krasa, Holly B, Johnston, Stephen S, Guiraud-Diawara, Alice, Kamat, Siddhesh A, Rohman, Patricia
Publicado no Neuropsychiatr Dis Treat (2015)